The researchers have identified a human protein complex, called SKI complex, that is important for viral replication for several human pathogens including influenza, COVID-19, SARS-CoV, MERS-CoV, SARS-CoV-2, Ebola, and Marburg.

Using a computational approach called site-identification by ligand competitive saturation (SILCS), developed by SilcsBio, chemical compounds were identified and predicted to bind to the pocket on a human protein in the complex. Compounds were tested to block replication of influenza virus in human cells as well as other viruses. Using this technology in combination with machine-learning tools, the researchers identified compounds with chemical structures similar to the active compounds to find ones that work better at blocking viral replication.

AGC Biologics, Molecular Partners develop COVID-19 protein therapy
AGC Biologics has partnered with clinical-stage biotechnology company Molecular Partners to create a protein therapy against SARS-CoV-2, the virus that...

Constant Therapeutics to begin phase II trial for COVID-19 therapy
Constant Therapeutics' peptide drug TXA127 will advance to phase II clinical trials for the treatment of hospitalized COVID-19 patients.

CSL Behring begins phase II study of COVID-19 therapy
CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory...

Medivir, SciLifeLab partner on SARS-CoV-2 inhibitors
Medivir, a Swedish pharmaceutical company, is partnering with SciLifeLab, a Swedish national research laboratory, to leverage their drug discovery and...